上海交通大学学报(医学版) ›› 2020, Vol. 40 ›› Issue (06): 814-819.doi: 10.3969/j.issn.1674-8115.2020.06.017

• 论著·临床研究 • 上一篇    

西酞普兰对抑郁症患者外周血miRNA-16/5- 羟色胺转运体通路的影响

钱时兴,房 圆#,孙 琳,仇 琦,林治光,肖世富,李 霞#   

  1. 上海交通大学医学院附属精神卫生中心老年科,上海 200030
  • 出版日期:2020-06-28 发布日期:2020-08-11
  • 通讯作者: 房 圆,电子信箱:fangyuan_8611@163.com。李 霞,电子信箱:ja_1023@hotmail.com。#为共同通信作者。
  • 作者简介:钱时兴(1982—)男,住院医师,硕士;电子信箱:qsx0102@163.com。
  • 基金资助:
    国家自然科学基金(81671402)。

Effect of citalopram on miRNA-16/serotonin transporter pathway in peripheral blood of patients with depression

QIAN Shi-xing, FANG Yuan#, SUN Lin, QIU Qi, LIN Zhi-guang, XIAO Shi-fu, LI Xia#   

  1. Department of Geriatrics, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
  • Online:2020-06-28 Published:2020-08-11
  • Supported by:
    National Natural Science Foundation of China (81671402).

摘要: 目的·探讨西酞普兰对抑郁症患者外周血miRNA-16/5-羟色胺转运体 (serotonin transporter,SERT)通路相关指标的影响。方法·将未服药的抑郁症患者45例(未服药病例组)、经药物治疗的抑郁症患者32例(药物治疗组)及健康对照者32名(健康对照组)纳入研究,行汉密尔顿抑郁量表17项(Hamilton Depression Scale-17 items,HAMD-17)评估。采用荧光定量PCR检测血浆miRNA-16表达水平,采用Western blotting检测血小板中SERT蛋白表达水平。对未服药病例组中医师处方予以西酞普兰治疗的14例患者进行2个月的随访,随访结束后进行HAMD-17评估,检测血浆miRNA-16及血小板SERT蛋白的表达水平。结果·血浆miRNA-16表达水平在3组之间比较,差异无统计学意义(F=0.421,P=0.657);血小板SERT蛋白表达水平在3组之间比较,差异无统计学意义(F=0.112,P=0.894)。随访研究结果显示:14例处方予以西酞普兰治疗的患者,2个月后HAMD-17评分降低(Z=-3.187,P=0.001),血浆miRNA-16表达水平升高(t=2.455,P=0.032),血小板SERT蛋白表达水平无变化(t=-0.750,P=0.470)。结论·5-羟色胺再摄取抑制剂类药物西酞普兰对抑郁症患者血浆miRNA-16的表达具有下调作用;血小板5-羟色胺的减少并非是由血小板膜上SERT蛋白减少这一变化引起,可能与SERT功能降低有关。

关键词: 西酞普兰, 抑郁症, 5-羟色胺转运体, miRNA-16

Abstract: Objective · To discuss the effects of citalopram on miRNA-16/serotonin transporter (SERT) pathway in peripheral blood of the patients with depression. Methods · Forty-five patients with depression without medication (untreated group), 32 patients with depression treated with medicine(drug treated group) and 32 healthy people (control group) were enrolled in the study. Hamilton Depression Scale-17 items were used to evaluate the depressive symptoms. The expression level of plasma miRNA-16 was detected by fluorescence quantitative PCR, and the level of SERT protein in platelets was detected by Western blotting. Fourteen of the baseline patients who were treated with citalopram were followed up for 2 months. After the follow-up, the evaluation of HAMD-17, the detection of miRNA-16 and SERT protein were conducted. Results · There was no significant difference in the expression level of plasma miRNA-16 among the three groups (F=0.421, P=0.657). There was no significant difference of SERT protein expression in the platelets among the three groups (F=0.112, P=0.894). The follow-up study showed that the HAMD-17 score decreased after 2 months (Z=?3.187, P=0.001), the average expression level of plasma miRNA-16 increased (t=2.455, P=0.032), and the expression of SERT protein in the platelets did not change (t=?0.750, P=0.470) in 14 patients who were treated with citalopram. Conclusion · Citalopram, a serotonin reuptake inhibitor, can down-regulate the expression of plasma miRNA-16 in patients with depression, and the decrease of the platelet serotonin is not caused by the decrease of SERT protein on platelet membrane, but may be related to the decrease of the SERT function.

Key words: citalopram, depression, serotonin transporter (SERT), miRNA-16

中图分类号: